Featured Press Releases

Smart Cups Sets New Goals For Fundraising Round Amid Upcoming Partnerships And Continued Growth

Smart Cups Sets New Goals For Fundraising Round Amid Upcoming Partnerships And Continued Growth

Cellino Launches the U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

Cellino Launches the U.S.’s First Nebula-Powered iPSC Foundry for Scalable Autologous Biomanufacturing

  • 24 Feb 2025

Cellino announced its collaboration with Mass General Brigham’s Gene and Cell Therapy Institute...

Secretome Therapeutics

Secretome Therapeutics' STM-01, a neonatal cardiac progenitor cell therapy for HFpEF, receives FDA Fast Track designation

Jabil acquires Pharmaceutics International, Inc

Jabil acquires Pharmaceutics International, Inc

In Afghanistan, WHO and UNICEF will launch a polio vaccination campaign utilizing the PharmaJet® Tropis® ID delivery system

In Afghanistan, WHO and UNICEF will launch a polio vaccination campaign utilizing the PharmaJet® Tropis® ID delivery system

Viralgen Partners with Trogenix to Advance AAV Gene Therapy for Glioblastoma

Viralgen Partners with Trogenix to Advance AAV Gene Therapy for Glioblastoma

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

Johnson & Johnson Announces U.S. Food and Drug Administration Approval of TECVAYLI + DARZALEX FASPRO for Relapsed/Refractory Multiple Myeloma.

  • Johnson & Johnson
  • 06 Mar 2026
ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

ulrich medical USA® Expands Commitment to Evidence-Based Spine Innovation; Appoints Alissa Calaway, RN, MSN as Director of U.S. Clinical Affairs

  • ulrich medical USA
  • 06 Mar 2026
Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

Cognito Therapeutics Announces $105 Million Oversubscribed Series C Financing to Advance Spectris™ in Alzheimer’s Disease.

  • Cognito Therapeutics
  • 05 Mar 2026
Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

Eton Pharmaceuticals Strengthens Rare Disease Portfolio with U.S. Commercialization Rights to HEMANGEOL® Oral Solution

  • Eton Pharmaceuticals
  • 04 Mar 2026
FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

FTC Warns PBM Practices Drive Higher Drug Costs as Employers Push Back

  • US-Rx
  • 03 Mar 2026
30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

30% Lower Risk With WELIREG® + LENVIMA® vs. Cabozantinib in Previously Treated RCC

  • Merck & Co., Inc.
  • 03 Mar 2026
Drug Discovery 2024
The Digital Pharma Advances Conference 2026

Most Popular
March   2026
M T W T F S S
            1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31          

User Area

Discover

Engage with Us

© Pharmaceutical Era — A product of HISSM. All Rights Reserved.